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Objectives: Patients with RA have a higher risk of ischemic cardiac events com-
pared with the general population. This would be explained not only by the greater 
presence of traditional risk factors, but also by the systemic inflammatory nature 
of the disease. Compare self-reported prevalence of risk factors in rheumatoid 
patients with prevalence data from the brazilian general population. MethOds: 
Cross-sectional study between July and November 2014 including 183 patients with 
rheumatoid arthritis of both sexes, aged 20 years or older, in primary or secondary 
care units of the city of Blumenau, southern Brazil. Data collection was conducted 
through structured personal interview and, if needed, later complemented by phone. 
The national survey Vigitel 2012 was used to collect data from brazilian general 
population. Results: The target population consisted of 183 patients, 153 (83.6%) 
were female, mean age of 56.9 years and mean duration of disease of 12.1 years. The 
prevalence of self-reported comorbidities of the target population when compared 
with general population prevalence was respectively: hypertension 44.8% versus 
28.3%, diabetes mellitus 9.2% versus 12.5%, dyslipidemia 22.9% versus 16.5%, over-
weight 41.5% versus 35.8% and obesity 18.5% versus 19.1%, prior smoking 45.9% ver-
sus 23.4%, current smoking 8.7% versus 12.8%, physical inactivity 65% versus 14.2%. 
Positive family history for cardiovascular disease was observed in 42% of rheumatoid 
patients, that shows mean body mass index of 26.3 kg/m2. cOnclusiOns: The 
study result shows that the self-reported prevalence of traditional risk factors for 
ischemic heart disease in patients with rheumatoid arthritis in Blumenau is higher 
than the national prevalence of hypertension, dyslipidemia, overweight, previous 
smoking and physical inactivity. By contrast, the prevalence is lower for diabetes 
mellitus and current smoking.
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Objectives: To examine the resource utilization and direct costs of care in severe 
spondyloarthritis (SpA) patients based on a national representative claims data-
base. MethOds: The EGB Database is a national representative random sample of 
1 out of every 97 individuals covered by the main French public health insurance 
schemes, listing all healthcare consumption and allowing identification of beneficiar-
ies eligible for full health insurance coverage due to severe conditions. The annual 
economic burden related to severe SpA was estimated by comparing direct medical 
expenses (outpatient care and hospitalization costs) in the SpA adult (≥ 18 years) 
population to a control group (i.e. patients not in “Affection de Longue Durée” for 
severe SpA in 2012) matched for age and sex, using non-parametric Mann-Whitney 
tests. Overall cost (healthcare utilization and associated costs) was assessed from 
the Health Insurance perspective for 2012. Results: Among 470,326 adults in the 
database, 827 patients presenting with severe SpA were identified, corresponding to 
a nationwide prevalent population estimate of 88,275 patients in France in 2012. High 
blood pressure, recurrent major depressive disorders and other comorbidities taken as 
a whole were significantly more frequent in severe SpA patients than controls (4.5% 
vs 1.8%, p< 0.0001; 3.1% vs 1.5%, p= 0.003 and 24.7% vs 18.8%, p= 0.0003, respectively). 
Annual medical costs per severe SpA patient were 3.5 times higher than that of 
controls (mean costs: € 6,122±8,179 vs € 1,682±5,769, p< 0.0001; median costs: € 2,519 
vs € 300). The main contributors to this incremental cost were (mean values): medica-
tions (+€ 2,390, 53.8%), hospitalization (+€ 1,038, 23.4%) and healthcare professional 
consultations (+€ 716.7, 16.2%). The annual economic burden related to severe SpA in 
France in 2012 is estimated around € 391M. cOnclusiOns: The burden of severe SpA 
is significant in France with regard to comorbidities and medical costs supported by 
the healthcare system, as identified in this representative database analysis.
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Objectives: The changes of vitamin D level influencing bone metabolism are sea-
sonal, the effect of seasons on femoral neck fracture healing is unknown. The aim of 
our study was to determine the effects of seasonal periodicity on incidence of oste-
onecrosis following primary osteosynthesis of femoral neck fractures in Hungarian 
elderly population. MethOds: This nationwide retrospective observational cohort 
study based on dataset of National Health Insurance Fund Administration. Patients 
over 60 years undergoing internal fixation after primary femoral neck fracture 
(ICD10-S7200) and were discharged in 2000 were identified. Inpatient cases devel-
oping osteonecrosis were registered during the 8 years follow-up. The following 
factors were evaluated: sex, age, type of fracture, season of surgical intervention, 
day of surgery, surgical delay and comorbidities. The effect of seasons on survival 
time was investigated by Kaplan–Meier analysis and log-rank test. The crude inci-
dence rate ratios of osteonecrosis were calculated for factors. The impact of risk 
factors on the hazard of osteonecrosis was estimated by Cox proportional hazard 
model. Results: 3312 patients fit the criteria. During the observation period 106 
osteonecrosis (3.2%) were identified, yielding an overall incidence 8.87 per 1000 
person-years. The crude incidence rates were 14.38, 8.57, 6.58, and 5.70 per 1000 
person-years in winter, spring, summer, and fall. No significant differences were 
found in survival with respect to season with Kaplan–Meier analysis (p= 0.173). 
data was collected via phone calls through a specific questionnaire answered by 
PM women aged ≥ 50 years old (yo) who were in the registry and contacted directly 
by SPR researchers. Results: We surveyed 1.587 PM women with a mean age of 
66.0 yo (SD= 9.2). 43% had PM osteoporosis, but only 38.4% of women had previous 
knowledge of it. Previous diagnosis was mostly done by primary care physicians 
(57.9%). Less than a tenth (9.1%) had osteoporosis treatment. The most common 
pharmaceutical treatment was oral bisphosphonates (19.8%), followed by stron-
tium ranelate (7.8%). 199 women (12.5%) had stopped osteoporosis treatment in the 
12-month period previous to the questionnaire. This decision was driven by patients 
(61.3%) followed by the physicians (36.2%) and self-reported reasons were economic, 
polymedication, efficacy, gastrointestinal adverse events and other safety concerns. 
Of special interest, gastrointestinal adverse events were self-reported by more than 
a third of those women ever treated for osteoporosis (36.1%). This led to more health-
care consumption and treatment changes. cOnclusiOns: In this report, using a 
large sample from a patient registry, we observed low rates of treatment and high 
levels of therapy discontinuation in Portugal. A further understanding of underlying 
reasons for under-treatment and non-persistence is crucial to attain better health 
outcomes in post-menopausal osteoporosis.
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Objectives: Osteoporosis and chronic inflammatory rheumatic diseases (CIRD), 
including rheumatoid arthritis (RA), psoriatic arthritis (PA) and ankylosing spon-
dylitis (AS), are major issues in rheumatology. In these two therapeutic areas, data 
are needed to describe burden of disease and clinical management. Our objective 
was to identify patients likely to have osteoporosis or CIRD within French claims 
database, before running analyses. MethOds: As there is no diagnosis code in the 
database, treatment pattern or medical resource utilization were used to identify 
patients. Patients with osteoporosis were identified using age (≥ 50), reimbursement 
of anti-osteoporotic agents (ATC codes), osteoporosis-related hospitalization, or 
Long Term Disease (LTD) status, based on ICD-10 codes. For CIRD, the study popula-
tion included 3 sub-groups: patients with RA, PA and AS. For AS, identification was 
based on hospitalizations and LTD status for ICD-10 codes M08.1, M08.8, M08.9, 
M45, and M46. Identification for RA was based on ICD-10 codes M05, M06, M08.0, 
M08.2, M08.4 and M13. Identification for PA was based on ICD-10 codes M07 and 
M09. Results: Identification criteria for osteoporosis allowed to identify 7,939 
patients, corresponding to 4.5% of the French population ≥ 50 years. This popula-
tion consists of 92% of women and mean age is 71.6 years. Identification criteria 
selected 2,070 for RA, 923 patients for SA, and 492 patients for RP, corresponding 
to 3,223 patients with CIRD disease (0.62% of French population) cOnclusiOns: 
4.5% of patients of the French population have osteoporosis based on our selection 
criteria; a majority are old women, in line with the literature. For CIRD, 3,223 patients 
were identified, which is also consistent with the literature. Next steps will include 
the description of treatment patterns and the burden of  disease.
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Objectives: In France, the ECLAIR non-interventional, multicenter study was 
initiated to follow up real-world, moderate-to-severe, active RA patients treated 
with certolizumab pegol (CZP), prospectively for up to 3 years. In 2003, prescrip-
tion of glucocorticoids (GCs) in French patients with active RA was evaluated,1 
showing that > 50% received GCs, although GC use has not been comprehensively 
studied to date.1The objective is to describe baseline characteristics of French 
RA patients starting CZP, such as disease and treatment history, and concomi-
tant medication. MethOds: The ECLAIR study, run by 170 rheumatologists and 
6 internal medicine specialists, was designed to be representative of the French 
RA population. Baseline data, collected from treating physicians and patients via 
questionnaires, included history of RA treatments and concomitant diseases and 
their treatments. Results: 791 patients were included: 790 were used for analysis, 
1 was excluded for lack of signed informed consent. Patient characteristics: mean 
(SD) age 55.0 (13.1); 78.7% female; RA duration 8.9 (9.1) years; 73.4% rheumatoid 
factor positive; DAS28(ESR) 4.9 (1.3); disease activity moderate for 50.1% and high 
for 41.1% of patients. Mean HAQ-DI total score: 1.28 (0.69). Concomitant diseases: 
23.2% (183/790) of patients had vascular disorders, 19.1% (151/790) metabolism and 
nutrition disorders and 17.5% (138/790) musculoskeletal and connective tissue dis-
orders. Concomitant treatments included NSAIDs in 35.2% of patients, steroids in 
51.4% of patients and cDMARDs in 64.6% of patients (MTX: 53.5%, leflunomide: 9.0%, 
hydroxychloroquine: 2.8%, sulfasalazine: 2.4%, azathioprine: 0.3%, thalidomide: 
0.1%). cOnclusiOns: ECLAIR is the first anti-TNF, prospective, real-world study 
conducted in France, providing insights into the population of RA patients treated 
with anti-TNF therapy such as CZP. Baseline data showed that half of patients on 
CZP received GCs, similar to previous reports in the French RA population.1Further 
targeted statistical analyses on ECLAIR data could clarify trends associated with 
concomitant medication. REFERENCES: 1. Saraux A. J Rheumatol 2006 Jul;33:1258-6
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clinical diagnosis (degree I-III). 141 healthy subjects from Xi’an city were chosen and 
matched by age and sex. The study was performed in accordance with the Declaration 
of Helsinki and approved by the Human Ethics Committee of Xi’an Jiaotong University. 
Informed written consent was obtained from each subject. The staple food ( flour, 
rice and corn hazel) and hair from children and healthy subjects were collected. 
The selenium level in hair and staple food was tested with Atomic Fluorescence 
Spectrophotometer. Results: About 65 children which the total number of children 
was 1743 were KBD X-ray positive. The selenium level in hair of children from xunyi 
county was significantly lower than healthy subjects from Xi’an city (0.24 and 0.62 
μ g/g respectively, P< 0.05). No difference was found in selenium level of staple food 
between children from xunyi county and the control group (P> 0.05). cOnclusiOns: 
The abnormal ration of X-ray in children from xunyi county was lower than 5%. 
Although prevention and control measures have been implemented, the selenium 
level in hair of children from xunyi county was still lower. Children lived in xunyi 
county should intake more Se to prevent KBD. This research is supported by National 
Natural Science Foundation (No. 81172610), Huimin projects of Ministry of Science and 
Technology (No. 2012GS610101), Science and technology projects of Shaanxi province 
health department (No. 2014ZD072) and projects of Shaanxi Province Administration 
of traditional Chinese Medicine (13-LC085).
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Objectives: Excessive fluoride ingestion causes a disease known as fluoro-
sis which prevailing in more than 50 countries and regions. A large number of 
studies have shown that excess fluoride can cause human reproductive system 
damage. Therefore, we investigated the possible association between estrogen 
(E2) level with fluorosis and the role of selenium in fluorosis women in Shaanxi 
province. MethOds: Ziyang County of Ankang City has higher environmental 
selenium level, while the Hanbin district of Ankang City has lower environmental 
selenium level. Ziyang County and Hanbin district of Ankang City were both the 
serious fluorosis areas. The fluorosis women patients from different environmental 
selenium level area and the healthy volunteer were divided into three groups: “High 
Se + F group” (n= 50), “High F group” (n= 50) and “Control group” (n= 46). All women 
were among 20 to 49 years old. E2 level was examined by ELISA kit. The selenium 
level in hair was tested with Atomic Fluorescence Spectrophotometer. Results: 
The E2 was significantly lower in “High F group” than that in “High Se + F group” 
and “Control group” (27.11±1.91, 60.22±6.95, 63.57±2.24 pg/ml, respectively). The 
mean for total Se concentration in hair was different: 3.67±0.16 μ g/g in “High Se 
+ F group”, 0.99±0.09 μ g/g in “High F group” and 0.66±0.13 μ g/g in “Control group”, 
respectively. cOnclusiOns: The E2 level in fluorosis women was lower than that 
in control group women, while the Se has the protective effect against fluoride by 
increasing the E2 level. Women lived in fluorosis areas should intake more Se to 
prevent ovarian function damage induced by fluoride. This research was supported 
by National Natural Science Foundation (No. 81172610), Huimin projects of Ministry 
of Science and Technology (No. 2012GS610101), Science and technology projects 
of Shaanxi province health department (No. 2014ZD072) and projects of Shaanxi 
Province Administration of traditional Chinese Medicine (13-LC085).
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Objectives: To assess the budget impact of tofacitinib standardization in Brazilian 
private healthcare system for the treatment of moderate to severe Rheumatoid 
Arthritis (RA). MethOds: An analytical decision-making model was developed in 
order to simulate the costs of standardization of tofacitinib in the list of therapies 
available for the treatment of moderate to severe RA in the supplemental healthcare 
system (SS) in a time horizon of five years. The reference population was composed 
by applying the RA prevalence in the Brazilian population to the number of SS ben-
eficiaries for the year of 2015 which result n= 233,722 beneficiaries. For the analysis, 
the tofacitinibe cost of treatment was compared to the average cost of the therapy 
with a biological DMARD. For both, the following were also taken into consideration: 
(i) drug cost – an estimate through the technology list price; (ii) assumed projection 
for tofacitinib diffusion rate in the private healthcare system; (iii) micro-costing 
of disease follow-up costs; (iv) micro-costing of (subcutaneous and intravenous) 
administration costs; (v) market share of biological therapies in the Brazilian market, 
for which projection was obtained from IMS Health data (2014). All monetary units 
were in BRL. Results: The total cost of tofacitinib treatment is lower than the 
mean total cost of treatment with biological DMARDs, with an approximate reduc-
tion of 25.22%. Considering the assessed time horizon and the estimated diffusion 
rate for tofacitinib in relation to the biological therapy for SS beneficiaries in 2015, 
tofacitinib may yield savings of approximately 2% in 2015, 3% in 2016, 4% in 2017, 
5% in 2018, 6% in 2019, adding up an accrued of approximately 20% in the first five 
years of its standardization in the SS. cOnclusiOns: The use of tofacitinib may 
decrease the total treatment costs in the Brazilian private healthcare system for 
patients with moderate to severe RA.
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Significant correlations were revealed between the occurrence of osteonecrosis 
and age (year, HR= 0.974), female gender (female/male, HR= 2.978), fracture displace-
ment (displaced/non-displaced, HR= 1.998) and the season of surgery (fall/winter, 
HR= 0.372; spring/winter, HR= 0.602, summer/winter, HR= 0.455). cOnclusiOns: 
Wintertime osteosynthesis increases the risk of osteonecrosis. The findings raise 
the possibility of association between seasonal changes in vitamin D levels and 
impaired fracture healing of femoral neck fracture. The results may help establish 
an effective strategy for the prevention of serious complications.
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Objectives: Hip fractures are followed by increased mortality in the elderly. The 
study was carried out to analyse the mortality rate and predictors for mortality 
over 10 year period in patients over 60 years suffered from primary femoral neck 
fractures. MethOds: Data from patients aged 60 years and over undergoing pri-
mary surgical treatment after femoral neck fractures in the year 2000 were collected 
from database of Hungarian National Health Insurance Fund. The mortality was 
analysed for the period 2000-2010. The following risk factors were investigated: age, 
gender, type of fracture, comorbidities, type of surgery, time to surgery and further 
surgical treatment. Predictors for mortality were evaluated by Cox proportional 
hazard model and logistic regression analysis using yearly intervals. The patients’ 
survival was investigated by Kaplan-Meier analysis and log-rank test. Results: 
3783 patients were included the study. The mortality rate was 30.76% in the first 
year, and 80.65% at 10 years. The mortality showed a tendency to decrease during the 
follow-up period. Cox regression identified higher age (years, HR= 1.024), male gen-
der (female/male, HR= 0.776), fracture type (extracapsular/GardenI-II, HR= 1.276, and 
GardenIII-IV/GardenI-II, HR= 1.194), comorbidities (presence/absence, HR= 1.361), 
type of surgical methods (arthroplasty/osteosynthesis, HR= 0.750), surgery delay 
more than 12 hours (12-24/0-6 hours, HR= 1.188) and absence of further surgical 
treatment (presence/absence, HR= 0.756) as significant risk factors for overall mor-
tality. Logistic regression analysis showed significantly higher risk of men up to 5 
years, higher age up to 10 years, comorbidities up to 4 years, type of fracture and 
surgical delay of the primary treatment up to 2 years. Kaplan-Meier method gave 
parallel results with risk factor analysis. cOnclusiOns: Assessing the impact of 
risk factors on 10 year mortality after primary femoral neck fracture is difficult. We 
found associations between clinical determinants and late mortality, which require 
further investigations regarding the long period of time until death.
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Objectives: Glutathione peroxidase 1 (GPx1) is a ubiquitously expressed sele-
nium-dependent enzyme that protects cells against oxidative damage by reducing 
hydrogen peroxide and a wide range of organic peroxides. In the present study, we 
investigated the possible association between the proline-leucine polymorphism 
(198Pro/Leu, rs1050450) present in the GPx1 gene and the susceptibility of Kashin-
Beck disease (KBD) in a Chinese population. Meanwhile, we detected the mRNA 
expression of GPx1 in blood and cartilage tissues between KBD and controls in 
order to analyze the transcriptional activity of GPx1 and explore molecular mecha-
nism of KBD. MethOds: The GPx1 Pro198Leu genotype was determined in 161 
KBD cases and 312 control individuals with polymerase chain reaction-restriction 
fragment length polymorphism assay (PCR-RFLP). The mRNA expression level of 
GPx1 was detected by Real-time PCR. Results: The genotypic and allelic frequency 
of GPX1 were different statistically between KBD patients and healthy controls 
(P= 0.016, 0.043, respectively). We found an overall protective effect of the Pro/Pro 
genotype on the risk of KBD. Carriers of Pro/Leu and Leu/Leu had an increased risk 
of KBD compared with homozygous wild-type (Pro/Pro) individuals (OR, 1.781; 95% 
CI, 1.127-2.814; P = 0.016). The results of Real-time PCR showed a significant dif-
ference of mRNA level of GPx1 in whole blood between the two groups (P= 0.026), 
and expression of GPx1 mRNA in KBD patients decreased significantly coampared 
with controls. However, no significant difference was observed in cartilage tissues 
(P= 0.162). cOnclusiOns: The study suggested that the 198Pro/Leu polymorphism 
of GPx1 gene might be a genetic risk factor for KBD in the Chinese population. These 
results also indicated that this polymorphism at the GPx1 locus was a common 
event in KBD development and that expression of GPx1 mRNA in KBD patients 
decreased significantly compared with controls might be involved in the pathogen-
esis of KBD. *This research is supported by National Natural Science Foundation of 
China (No. 30671820, 81172610).
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Objectives: Kashin-Beck disease (KBD) is a chronic osteoarthropathy, prevailing in 
selenium (Se)-deficiency regions, while its etiopathogenesis maintains obscure. The 
disease mainly affects children, Se supplementation was effective in preventing KBD. 
However, Se supplementation could not entirely prevent KBD. Therefore, we investi-
gated possible association between Se and susceptibility to KBD in Xunyi county of 
Shaanxi province. MethOds: 140 children who were 7-12 years old from 14 towns of 
Xunyi county were enrolled by radiography examination (X-ray of the right hand) and 
